M13 filamentous phage Inibidores

Os inibidores comuns do fago filamentoso M13 incluem, entre outros, a rifampicina CAS 13292-46-1, o ácido nalidíxico CAS 389-08-2, a mitomicina C CAS 50-07-7, a novobiocina CAS 303-81-1 e a ciprofloxacina CAS 85721-33-1.

M13 filamentous phage inhibitors refer to a class of molecules specifically designed to target and disrupt the replication and spread of M13 filamentous bacteriophages. These inhibitors are of particular interest in the field of molecular biology and biotechnology, where the use of M13 phage vectors plays a crucial role in various genetic engineering and phage display applications. M13 filamentous phages are a type of bacteriophage that infects the bacterium Escherichia coli (E. coli) and has a unique filamentous morphology. They are widely used as cloning vectors due to their ability to carry and present foreign DNA on their surface, which makes them valuable tools for generating recombinant proteins, mapping epitopes and selecting specific peptides or antibodies.

Inhibitors designed to attack M13 phages usually work by interfering with various stages of the phage life cycle. This can include blocking phage binding to host E. coli cells, inhibiting phage DNA replication, preventing phage assembly and release, or disrupting the phage/host interaction in some other way. These inhibitors are developed through a combination of molecular biology, structural biology and chemical synthesis techniques. Their efficacy is evaluated in vitro and in experimental environments to verify their ability to prevent or limit the proliferation of M13 filamentous phages, ensuring the integrity and success of various biotechnological applications that depend on the use of these phage vectors.